Dear Editor,

An 80-year-old man with a history of fibromyalgia, arthralgias, and arterial hypertension presented for the recurrence of a skin lesion on the right infraorbital region. Three years earlier, an incisional biopsy reported actinic keratosis and the lesion was treated with cryotherapy and topical diclofenac 3% gel, with only partial improvement.

On physical examination, an erythematous, scaly, well-demarcated plaque of 5.5 cm in diameter was present on the lower eyelid, extending to the medial canthus of the right eye. Ectropion was also evident (Figure 1A). Histological examination of a new incisional biopsy revealed the presence of cutaneous squamous cell carcinoma in situ with a focal invasion of the dermis (Figure 1B).

FIGURE 1  (A) Erythematous, scaly, and well-demarcated plaque located on the lower eyelid, extending up to the medial corner of the eye. (B) Histopathology of the lesion: squamous cell carcinoma, extensive intraepithelial component with solid token into the dermis (hematoxylin and eosin stain, × 5 magnification). (C) Clinical aspect of the lesion after 1 month of imiquimod 3.75% cream application: marked reduction in lesional size with crusts (crusting is an expected effect of topical imiquimod. (D) Clinical aspect of the lesion after 6 months of imiquimod 3.75% cream application: clear clinical improvement of the disease, without macroscopical signs of residual neoplasia

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2022 The Authors. Dermatologic Therapy published by Wiley Periodicals LLC.

Dermatologic Therapy. 2022;35:e15800.  
https://doi.org/10.1111/dth.15800
Following multidisciplinary tumor board discussion, surgical and radiation therapy were discouraged due to the high risk of potentially irreversible functional impairment and scarring. The patient was thus started on cemiplimab 350 mg i.v. every 3 weeks. Despite initial clinical improvement, subsequent severe worsening of arthralgias warranted the interruption of the treatment after seven courses. Therefore, after written informed consent, off-label treatment with topical 3.75% imiquimod daily for two consecutive weeks was prescribed. After two courses of two consecutive weeks, we observed a marked reduction in lesional size (Figure 1C). The treatment was well tolerated. Because of partial response, the patient was advised to apply two more courses of topical 3.75% imiquimod. After 6 months, complete response was evident (Figure 1D). In addition, the patient did not report any local or systemic adverse effects from the application of the topical drug.

Imiquimod (1-(2-2methylpropyl)-1H-imidazo [4, 5-c] quinolin-4-amine) is a non-nucleoside heterocyclic amine that activates toll-like receptor (TLR)-7 and -8 inducing activation of the innate and adaptive immune systems. Imiquimod exerts its action through host immunity rather than as a direct antiviral agent.

Topical 5% imiquimod is licensed by the European Medicines Agency for the management of superficial basal cell carcinomas (sBCCs), actinic keratoses, and external genital warts in adult patients, while the 3.75% formulation is only approved for the topical management of typical, non-hyperkeratotic and non-hypertrophic actinic keratoses on the face or balding scalp in immunocompetent adults. Nevertheless, since its approval, numerous off-label uses for imiquimod have been studied, including squamous cell carcinomas (SCCs) in situ.

Locally advanced squamous cell carcinoma is defined as nonmetastatic cSCC who cannot undergo surgery or radiation therapy, because of invasion, infiltration recurrences, large size, or when complete resection would cause intolerable complications.

In our patient, cemiplimab was administered as first-line treatment for a locally advanced SCC of the eyelid. However, poor clinical response in association with worsening of arthralgias was observed. We thus chose the 3.75% concentration of imiquimod due to its better tolerability and anatomical location.

Dealing specifically with the periocular region, a recent literature review showed that almost half of the patients treated with topical imiquimod in this area developed ocular side effects, typically conjunctivitis, blink discomfort, and keratitis. Most of these issues were however generally mild and resolved a few days after withdrawal of the drug.

To our knowledge, only three cases reporting application of topical imiquimod 3.75% for SCC have been published to now, one localized in the penis, one in the scalp, and one in the cheek. However, no data are available for the treatment of locally advanced SCC in the periocular region with topical 3.75% imiquimod.

In conclusion, application of topical 3.75% imiquimod daily for seven courses led to complete regression of the tumor, while no severe side effects requiring withdrawal of the therapy were detected. This immune response modifier drug, at a lower concentration, could be a useful alternative therapeutic option in patients with minimally invasive squamous cell carcinomas in difficult-to-treat areas who cannot undergo surgery, radiation, or systemic therapy. Further studies would nonetheless be required to confirm the effectiveness of topical 3.75% imiquimod in a larger cohort of patients, evaluate the long-term response, and establish the occurrence of relapses.

**AUTHOR CONTRIBUTIONS**

Francesco Toso: Data collection, writing—original draft preparation, writing—review & editing. M. Chiara Tronconi, Andrea Cortese, Giovanni Fiorillo, Alessandra Bressan: Conceptualization, writing—original draft preparation, writing—review & editing. Antonio Costanzo, Riccardo G. Borroni: Conceptualization, writing—original draft preparation, writing—review & editing. All authors reviewed the results and approved the final version of the manuscript.

**ACKNOWLEDGMENT**

Open access funding provided by BIBLIOSAN.

**CONFLICT OF INTEREST**

The authors declare no conflict of interest.

**DATA AVAILABILITY STATEMENT**

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Francesco Toso
M. Chiara Tronconi
Andrea Cortese
Giovanni Fiorillo
Alessandra Bressan
Antonio Costanzo
Riccardo G. Borroni

1Dermatology Unit, Humanitas Research Hospital-IRCCS, Rozzano, Italy
2Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
3Oncology Unit, Cancer Center, Humanitas Research Hospital-IRCCS, Rozzano, Italy
4Pathology Unit, Humanitas Research Hospital-IRCCS, Rozzano, Italy

Correspondence
Francesco Toso, Department of Biomedical Sciences, Humanitas University, Dermatology Unit, Humanitas Research Hospital – IRCCS, Via Rita Levi Montalcini, 4 20090, Pieve Emanuele, MI, Italy.
Email: francesco.toso@humanitas.it

**ORCID**

Francesco Toso https://orcid.org/0000-0001-8531-5164
Andrea Cortese https://orcid.org/0000-0001-9500-444X
REFERENCES

1. Garland SM. Imiquimod. Curr Opin Infect Dis. 2003;16(2):85-89. doi: 10.1097/00001432-200304000-00004

2. Cantisani C, Lazic T, Richetta AG, Clerico R, Mattozzi C, Calvieri S. Imiquimod 5% cream use in dermatology, side effects and recent patents. Recent Pat Inflamm Allergy Drug Discov. 2012;6(1):65-69. doi: 10.2174/187221312798889301

3. Stratigos AJ, Garbe C, Dessinioti C, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: part

1. Epidemiology, diagnostics and prevention. Eur J Cancer. 2020;128:60-82. doi: 10.1016/j.ejca.2020.01.007

4. Avallone G, Merli M, Dell’Aquila C, et al. Imiquimod-side effects in the treatment of periorcular skin cancers: a review of the literature. Dermatol Ther. 2022;35(4):e15326. doi: 10.1111/dth.15326

5. Robustelli Test E, Fumo G, Corbeddu M, Ferreli C, Rongioletti F. Efficacy of Imiquimod 3.75% for the treatment of extensive Bowen’s disease of the face in an elderly patient. Dermatol Ther. 2020;33(2):e13263. doi: 10.1111/dth.13263